What does KARIPHARMA do?

KARIPHARMA is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”, a code that says little about what the company actually does. Private Limited, started on 21 March 2003, 1 establishment.

What is the address of KARIPHARMA?

The registered office of KARIPHARMA is located at Kerkstraat 14, 1742 Ternat.

Is KARIPHARMA still active?

Yes. According to the CBE (29 October 2026) KARIPHARMA is active, legal situation “Normale toestand”, started on 21 March 2003.

Is KARIPHARMA registered on Peppol?

Yes, KARIPHARMA is registered on the Peppol network with ID 0208:0479817428.

What is the enterprise number of KARIPHARMA?

The enterprise number of KARIPHARMA is BE0479817428.

When was KARIPHARMA founded?

KARIPHARMA was founded on 21 March 2003.

Who are the directors of KARIPHARMA?

According to the 2025 annual accounts, the directors of KARIPHARMA are: Pharmada BV.

Is KARIPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 21 March 2003; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did KARIPHARMA make in 2025?

KARIPHARMA posted a profit after taxes of € 108,353 in financial year 2025.

What is the revenue of KARIPHARMA?

As a small company, KARIPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 129,534.

KARIPHARMA (Private Limited) - Ternat - BE0479817428

Dossier KARIPHARMA, printed on 29 October 2026 from databakkes.be/en/0479817428/karipharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 35 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

KARIPHARMA from Ternat, company number BE0479817428, closed financial year 2025 with a result of € 108,353 after tax. For that financial year KARIPHARMA recorded a gross margin of € 129,534 and equity of € 632,727. Compared with financial year 2024, the result moved from € -35,216 to € 108,353. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.

What it is worth Growing

€ 632,727

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 108,353

▲ still € 35,216 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 41,083

▼ 52% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 108,000 paid out

100 % of the profit went to the shareholders, mostly to Pharmada (100 % of the shares). That is where the money ends up.

People and assets in 2025

Vehicles and equipment

€ 25,507

▼ 38% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 722

▲ 14% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 30,968

▲ 1% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 128,403 Gross margin 2022: € 128,403 First fiscal year in the series	€ 139,808 Gross margin 2023: € 139,808 ▲ 9% vs 2022 (€ 128,403) Favourable step	€ -9,821 Gross margin 2024: € -9,821 ▼ € 149,629 vs 2023 (€ 139,808) Unfavourable step	€ 129,534 Gross margin 2025: € 129,534 ▲ € 139,354 vs 2024 (€ -9,821) Favourable step	▲ € 139,354
Profit after taxes	€ 85,827 Profit after taxes 2022: € 85,827 First fiscal year in the series	€ 82,408 Profit after taxes 2023: € 82,408 ▼ 4% vs 2022 (€ 85,827) Unfavourable step	€ -35,216 Profit after taxes 2024: € -35,216 ▼ € 117,624 vs 2023 (€ 82,408) Unfavourable step	€ 108,353 Profit after taxes 2025: € 108,353 ▲ € 143,569 vs 2024 (€ -35,216) Favourable step	▲ € 143,569
Equity	€ 623,583 Equity 2022: € 623,583 First fiscal year in the series	€ 667,591 Equity 2023: € 667,591 ▲ 7% vs 2022 (€ 623,583) Favourable step	€ 632,374 Equity 2024: € 632,374 ▼ 5% vs 2023 (€ 667,591) Unfavourable step	€ 632,727 Equity 2025: € 632,727 Unchanged (€ 632,374) Favourable step
Total debts	€ 346,988 Total debts 2022: € 346,988 First fiscal year in the series	€ 237,849 Total debts 2023: € 237,849 ▼ 31% vs 2022 (€ 346,988) Favourable step	€ 232,091 Total debts 2024: € 232,091 ▼ 2% vs 2023 (€ 237,849) Favourable step	€ 195,051 Total debts 2025: € 195,051 ▼ 16% vs 2024 (€ 232,091) Favourable step	▼ 16%
Cash	€ 212,130 Cash 2022: € 212,130 First fiscal year in the series	€ 109,804 Cash 2023: € 109,804 ▼ 48% vs 2022 (€ 212,130) Unfavourable step	€ 85,844 Cash 2024: € 85,844 ▼ 22% vs 2023 (€ 109,804) Unfavourable step	€ 41,083 Cash 2025: € 41,083 ▼ 52% vs 2024 (€ 85,844) Unfavourable step	▼ 52%
Retained profit	€ 360,883 Retained profit 2022: € 360,883 First fiscal year in the series	€ 404,891 Retained profit 2023: € 404,891 ▲ 12% vs 2022 (€ 360,883) Favourable step	€ 369,674 Retained profit 2024: € 369,674 ▼ 9% vs 2023 (€ 404,891) Unfavourable step	€ 370,027 Retained profit 2025: € 370,027 Unchanged (€ 369,674) Favourable step
Dividend	€ 78,983 Dividend 2022: € 78,983 First fiscal year in the series	€ 38,400 Dividend 2023: € 38,400 ▼ 51% vs 2022 (€ 78,983) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 38,400) Unchanged	€ 108,000 Dividend 2025: € 108,000 Unchanged (€ 0) Unchanged
Balance sheet total	€ 970,570 Balance sheet total 2022: € 970,570 First fiscal year in the series	€ 905,440 Balance sheet total 2023: € 905,440 ▼ 7% vs 2022 (€ 970,570) Unchanged	€ 864,466 Balance sheet total 2024: € 864,466 ▼ 5% vs 2023 (€ 905,440) Unchanged	€ 827,778 Balance sheet total 2025: € 827,778 ▼ 4% vs 2024 (€ 864,466) Unchanged	▼ 4%

Key figures of KARIPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to KARIPHARMA?

What happened at KARIPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 17, 2026 New annual accounts for financial year 2025: profit of € 108,353. Source: NBB ↗
Mar 21, 2003 New establishment in Ternat. KBO
Mar 21, 2003 Start of the company according to the CBE. KBO

In short

From € 85,827 profit in 2022 to € 108,353 profit in 2025.

Paid € 66,422 in corporate taxes since 2022.

Best year ever: 2025, with € 108,353 profit.

Paid out € 225,383 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Pharmada 100%

The stake of Pharmada comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

KARIPHARMA

Apotheek Broechoven 100%

Behind KARIPHARMA is Pharmada BV. The shares are held by Pharmada (100%). It owns 100% of Apotheek Broechoven itself.

Directors

According to the 2025 annual accounts

Pharmada BV

Director · represented by Broechoven Kristel

Shareholders

Pharmada

100%

Participations

Apotheek Broechoven

100%

Establishments

Establishment units

Physical locations of this company

Registered office

Kerkstraat 14

1742 Ternat

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

APOTHEEK BROECHOVEN same network

€ 308,757 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0479.817.428
VAT number: BE 0479.817.428
Registered office: Kerkstraat 14, 1742 Ternat
Names & denominations: KARIPHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 21 March 2003
Peppol: Active · Active since 17 Sept 2025
Activities · NACE: Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗